Effective management of attention-deficit/hyperactivity disorder (ADHD) through structured re-assessment: the Dundee ADHD Clinical Care Pathway

被引:44
作者
Coghill, David [1 ]
Seth, Sarah [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Div Neurosci, Dundee DD1 9SY, Scotland
关键词
Attention-deficit/hyperactivity disorder; Titration; Treatment response; Inadequate response; MEDICATION ALGORITHM PROJECT; CONSENSUS CONFERENCE PANEL; LONG-TERM OUTCOMES; RATING-SCALE; MULTIMODAL TREATMENT; MULTIPLE REPORTS; PART II; CHILDREN; METHYLPHENIDATE; RELIABILITY;
D O I
10.1186/s13034-015-0083-2
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Attention-deficit/hyperactivity disorder (ADHD) has become a major aspect of the work of child and adolescent psychiatrists and paediatricians in the UK. In Scotland, Child and Adolescent Mental Health Services were required to address an increase in referral rates and changes in evidence-based medicine and guidelines without additional funding. In response to this, clinicians in Dundee have, over the past 15 years, pioneered the use of integrated psychiatric, paediatric, nursing, occupational therapy, dietetic and psychological care with the development of a clearly structured, evidence-based assessment and treatment pathway to provide effective therapy for children and adolescents with ADHD. The Dundee ADHD Clinical Care Pathway (DACCP) uses standard protocols for assessment, titration and routine monitoring of clinical care and treatment outcomes, with much of the clinical work being nurse led. The DACCP has received international attention and has been used as a template for service development in many countries. This review describes the four key stages of the clinical care pathway (referral and pre-assessment; assessment, diagnosis and treatment planning; initiating treatment; and continuing care) and discusses translation of the DACCP into other healthcare systems. Tools for healthcare professionals to use or adapt according to their own clinical settings are also provided.
引用
收藏
页数:14
相关论文
共 68 条
  • [1] [Anonymous], ATT DEF HYP DIS
  • [2] [Anonymous], ATT DEF HYP DIS CHIL
  • [3] [Anonymous], EUROPEAN CHILD AD S1
  • [4] [Anonymous], ESNM 19 ATT DEF HYP
  • [5] [Anonymous], LISD DIM 30 MG 50 MG
  • [6] [Anonymous], MANUAL ASFBA SCH AGE
  • [7] [Anonymous], ATT DEF HYP DIS SERV
  • [8] [Anonymous], METH AT DEX ATT DEF
  • [9] [Anonymous], MAN ATT DEF HYP DIS
  • [10] [Anonymous], INF RES PROF STRENGH